- Home
- RDN vs VKTX Comparison
RDN vs VKTX Comparison
Compare RDN & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDN | VKTX |
|---|---|---|
| Founded | 1977 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.4B |
| IPO Year | 2008 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RDN | VKTX |
|---|---|---|
| Price | $38.87 | $31.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $40.67 | ★ $95.86 |
| AVG Volume (30 Days) | 1.2M | ★ 2.2M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | ★ 5.61 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $1,197,084,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.66 | N/A |
| P/E Ratio | $43.72 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $31.50 | $22.96 |
| 52 Week High | $41.05 | $43.15 |
Technical Indicators
Market Signals| Indicator | RDN | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.44 | 36.28 |
| Support Level | $32.03 | $30.39 |
| Resistance Level | $41.05 | $33.40 |
| Average True Range (ATR) | 1.16 | 1.75 |
| MACD | -0.03 | -0.82 |
| Stochastic Oscillator | 58.14 | 15.08 |
Price Performance
Historical ComparisonAbout RDN Radian Group Inc.
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one reportable segment, Mortgage Insurance, which primarily derives its revenue by providing private mortgage insurance on residential first-lien mortgage loans to mortgage lending institutions and mortgage credit investors.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.